bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
HQMarcy-l'Étoile, FR
Size (employees)9,806 (est)+5%
bioMerieux was founded in 1963 and is headquartered in Marcy-l'Étoile, FR
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at bioMerieux

Alexandre MeRieux

Alexandre MeRieux

Chairman and CEO
Alain Pluquet

Alain Pluquet

Executive Vice President, Chief Data Officer
Randy Rasmussen

Randy Rasmussen

Executive Vice President, Molecular Biology
Kirk Ririe

Kirk Ririe

Executive Vice President, Chief Innovation Officer
Stefan Willemsen

Stefan Willemsen

Executive Vice President, Americas Region
Michel Baguenault

Michel Baguenault

Executive Vice President, Human Resources and Communications & Company Secretary
Show more

bioMerieux Office Locations

bioMerieux has an office in Marcy-l'Étoile
Marcy-l'Étoile, FR (HQ)
376 Chemin de l'Orme
Show all (1)
Report incorrect company information

bioMerieux Financials and Metrics

bioMerieux Revenue

Embed Graph
bioMerieux's revenue was reported to be €2.10 b in FY, 2016 which is a 7.1% increase from the previous period.

Revenue (FY, 2016)

2.1 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

1.1 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

179.2 m

EBIT (FY, 2016)

282.5 m

Cash (31-Dec-2016)

178.6 m


8.2 b
EURFY, 2014FY, 2015FY, 2016


1.7 b2 b2.1 b

Revenue growth, %


Cost of goods sold

853.9 m975.4 m1 b

Gross profit

844.5 m989.2 m1.1 b
EURFY, 2014FY, 2015FY, 2016


119.7 m147.1 m178.6 m

Accounts Receivable

449.3 m445.1 m465.8 m


299.2 m355.8 m404.4 m

Current Assets

991.4 m1.1 b1.2 b
EURFY, 2014FY, 2015FY, 2016

Net Income

135.5 m110.3 m179.2 m

Cash From Operating Activities

298.3 m310 m335.6 m

Purchases of PP&E

(158.1 m)(208.2 m)(233 m)

Cash From Investing Activities

(502.7 m)(208 m)(257.2 m)
EURY, 2016


29.2 x


24.6 x


224.3 k


0.3 x


0.1 x

Financial Leverage

1.9 x
Show all financial metrics

bioMerieux Operating Metrics

FY, 2015FY, 2016





Patents and Patent Applications

581 529
Show all operating metrics
Report incorrect company information

bioMerieux Online and Social Media Presence

Embed Graph
Report incorrect company information

bioMerieux News and Updates

POC Molecular Diagnostics 2018 Global Market Key Players – Abbott, bioMerieux, Danaher, BD, Certest Biotec, F. Hoffmann-La Roche – Analysis and Forecast to 2025 Presents “Global POC Molecular Diagnostics Market Size, Status and Forecast 2018-2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

HIV/AIDS Testing 2018 Global Market Key Players - Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Siemens.....

HIV/AIDS Testing – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Global $16.7 Bn Clinical Microbiology Market, 2018-2025 - Market is Dominated by bioMerieux, Cepheid, Danaher and Bruker

DUBLIN, Aug 16, 2018 /PRNewswire/ -- The "Clinical Microbiology Market Size, Share & Trends Analysis Report By Product, By Application (Bloodstream, Respiratory, Gastrointestinal, Periodontal, STD, UTI), By Region, And Segment Forecasts, 2018 - 2025" report has been added to...

IVD Industry Battles AMR, Touts Biotin-Free Immunoassays and Smaller Footprints at the 2018 American Association for Clinical Chemistry Meeting

ROCKVILLE, Md., Aug. 2, 2018 /PRNewswire/ -- Global in vitro diagnostic vendors and the laboratory professionals that make up their customers made the fight against anti-microbial resistance (AMR) a key focus of the American Association for Clinical Chemistry (AACC) meeting in Chicago, IL ...

Infection Surveillance Solutions Market Estimated to Exhibit 14.4% CAGR during 2017-2025

Global infection surveillance solution market to register a staggering 14.04% CAGR during the forecast- 2017 to 2025. The US$ 316.67 Mn market is likely to surpass US$ 900 Mn in revenues by 2025-end. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

bioMerieux Company Life and Culture

Report incorrect company information